3728 Jinke Rd, Bldg 1, West Wing, Shanghai, China info@tyligand.com
Who we are ?


Deep experience
Strong track record
Complementary skills
Aligned to deliver


Tony Zhang,PhD
Tony received his Ph.D. from Purdue University under the tutelage of Professor Eiichi Negishi (2010 Nobel Prize winner). Prior to founding Tyligand, he has served as the Senior Research Fellow of Small Molecule Design and Development of Eli Lilly, the founding Managing Director of Lilly China R&D Center, and the Vice President of Eli Lilly Global External R&D for Asia. He has also served as Chairman of BayHelix Group and adjunct professor of several leading universities.
Tony Zhang,PhD    Founder and CEO
Boyu Zhong,PhD
Dr. Zhong received Ph.D. in Medicinal Chemistry from Northwestern (Prof. Richard Silverman) and received postdoctoral training fellow at Caltech and Harvard. He has over 25 years experience in cancer research, leaving a long track record of drug hunting success at Eli Lilly, CrownBio, Immune Sensor, and Gan & Lee. Over 10 candidates to his credit have entered into trials, including Bozitinib/Vebreltinib, which was named after him and is the most selective kinase inhibitor known so far and is pending approval in US and China.
Boyu Zhong,PhD    Founder and President
Professor Zhong-Yin Zhang
Zhong-Yin Zhang is the distinguished Professor of Medicinal Chemistry, Robert C. and Charlotte P. Anderson Chair in Pharmacology, and Head of the Department of Medicinal Chemistry and Molecular Pharmacology. He also serves as the Director of the Institute for Drug Discovery at Purdue University. His research spans the disciplines of chemistry and biology with an emphasis on PTP structure and function, signaling mechanism, and development of PTP inhibitors as novel therapeutics.
Professor Zhong-Yin Zhang     Academic Founder
Cindy Li
Jing Cindy Li has extensive experience in the clinical development of innovative drugs. She has previously worked at Sanofi, HUTCHMED, and Transcenta, where she and her team successfully brought several drug to market in China and into global development. Her work experience covers the full life cycle of drug clinical development in support of making innovative medicines available to patients globally.
Cindy Li    VP, Clinical and Medical Science
Carl Xiao, PhD
Dr. Xiao has more than 10 years experience in pharmaceutical R&D and business development. He worked previously in Shanghai Pharmaceutical (Hong Kong), in charge of new drug R&D investment, 3SBio on business development, and Roche's early R&D. Dr. Kai Xiao received Ph.D. in Genetics and Genomics from the University of Florida School of Medicine, and MBA from the University of Florida School of Business.
Carl Xiao, PhD    VP, Business Development